ArticleThe Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques2011
The neuropathies of Waldenström's macroglobulinemia (WM) and IgM-MGUS.
Article in The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 59 citations in OpenAlex.
- Peripheral neuropathy in the phase 3 ASPEN study of Bruton tyrosine kinase inhibitors for Waldenström macroglobulinemia.Blood advances · 2025Trial
- Decoding Waldenström Macroglobulinemia Through Genomics, Epigenomics and Cellular Interactions.International journal of molecular sciences · 2026Review
- Autonomic Nervous System Phenotyping Across Chronic Demyelinating Peripheral Neuropathies: A Comparative Study.Journal of the peripheral nervous system : JPNS · 2026Article
- From tingling to treatment: well-interpreted ENMG unmasks Waldenström's macroglobulinemia: a case report.Acta neurologica Belgica · 2026Article
- Differential Diagnosis of Waldenström's Macroglobulinemia and Early Management: Perspectives from Clinical Practice.Blood and lymphatic cancer : targets and therapy · 2022Review
- Article
- IgM paraprotein and anti-MAG sensory polyneuropathy associated with Waldenstrom's macroglobulinaemia and medullary carcinoma of the thyroid.BMJ case reports · 2021Article
- Association of small-fiber polyneuropathy with three previously unassociated rare missense SCN9A variants.Canadian journal of pain = Revue canadienne de la douleur · 2020Article
- Neurological impairment in a patient with concurrent cervical disc herniation and POEMS syndrome.European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society · 2019Review
- Waldenstrom-associated anti-MAG paraprotein polyneuropathy with neurogenic tremor.BMJ case reports · 2019Article
- POEMS syndrome: clinical update.Journal of neurology · 2019Review
- Clinical spectrum of Castleman disease-associated neuropathy.Neurology · 2016Article
- Neuropathies associated with lymphomaNeuro-oncology practice · 2015Review
- Neuromuscular issues in systemic disease.Current neurology and neuroscience reports · 2015Review
- Immunotherapy-based regimen in anti-MAG neuropathy: results in 45 patients.Haematologica · 2013Article
- IgM-monoclonal gammopathy neuropathy and tremor: a first epidemiologic case control study.Parkinsonism & related disorders · 2012Article
- Amyloid-like IgM deposition neuropathy: a distinct clinico-pathologic and proteomic profiled disorder.Journal of the peripheral nervous system : JPNS · 2012Article
- An update on monoclonal gammopathy and neuropathy.Current neurology and neuroscience reports · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundNeuropathy is common in Waldenström's macroglobulinemia (WM, an IgM-associated lymphoplasmacytic lymphoma) and in IgM-monoclonal gammopathy of undetermined significance (IgM-MGUS). Paraneoplastic or paraimmune mechanisms are thought to be involved in the pathogenesis of these neuropathies. Attempts at distinguishing WM and IgM-MGUS neuropathies are lacking especially among bone marrow (BM) confirmed patients.
methodsRetrospective analyses were performed on BM confirmed WM (N=30) and IgM-MGUS (N=73) neuropathy patients with neurologic assessments and hematologic features.
resultsThe presence of anemia and quantity of IgM monoclonal protein were significantly greater in WM. Based on multiple neurologic assessments differences were not found for: 1) length of time from neurologic symptom onset to evaluation; 2) chief complaint of painless loss of feeling in the feet, Romberg's sign and tremor; and 3) clinical motor, sensory and reflex abnormalities. Autonomic testing was normal in both diseases. Using nerve conduction (NCS) criteria for demyelination, 62% of IgM-MGUS and 27% of WM met this criteria (p=0.013). IgM MGUS patients had greater terminal conduction slowing by ulnar residual latency calculation (<0.01). The degree of axonal loss as measured by summated compound muscle action potentials and available nerve biopsy was not significantly different between diseases.
conclusionAlthough WM and IgM-MGUS must be distinguished for hematologic prognosis and treatment, clinical neuropathy presentations of WM and IgM-MGUS are similar and likely related to comparable axonal loss in both conditions. Despite these similarities, evidence of demyelination was found by electrophysiologic studies much more commonly in IgM-MGUS. This difference may reflect varied immune mechanism(s) in the two disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.